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Globaldeficiencyof11-hydroxysteroiddehydrogenase1 (11-HSD1), anenzymethat regenerates
glucocorticoidswithin cells, promotes angiogenesis and reduces acute infarct expansion following
myocardial infarction (MI) suggesting that 11-HSD1 activity has an adverse influence on wound
healing in the heart after MI. The present study investigated whether 11-HSD1 deficiency could
prevent the development of heart failure following MI, and examined whether 11-HSD1 defi-
ciency in cardiomyocytes and vascular smoothmuscle cells confers this protection. Male mice with
global deficiency in 11-HSD1, or with Hsd11b1 disruption in cardiac and vascular smooth muscle
(via SM22-Cre recombinase) underwent coronary artery ligation for induction ofMI. Acute injury
was equivalent in all groups. However, by 8 weeks after induction of MI, relative to C57Bl/6 wild
type, globally 11-HSD1 deficient mice had reduced infarct size (34.72.1%LV vs 44.03.3%LV,
P0.02), improved function (ejection fraction 33.52.5% vs 24.72.5%, P0.03) and reduced
ventricular dilation (LVEDV 0.170.01ml vs 0.210.01ml, P0.01). This was accompanied by a
reduction in hypertrophy, pulmonary edema and in the expression of genes encoding atrial na-
triuretic peptide and-myosin heavy chain. Noneof these outcomes, nor promotionof peri-infarct
angiogenesis during infarct repair,were recapitulatedwhen11-HSD1deficiencywas restricted to
cardiac and vascular smooth muscle. 11-HSD1 expressed in cells other than cardiomyocytes or
vascular smooth muscle limits angiogenesis and promotes infarct expansion with adverse ventric-
ular remodeling after MI. Early pharmacological inhibition of 11-HSD1 may offer a new thera-
peutic approach to prevent heart failure associated with ischemic heart disease.
Interventions to restore perfusion following myocardialinfarction (MI) have significantly enhanced acute sur-
vival (1). However many patients survive with injury to
their myocardium that is replaced during wound healing
bynoncontractile scar tissue. In the longer term structural,
functional and metabolic remodeling of the remaining
ventricle to compensate for contractile deficiency and al-
teration in wall stress promotes progression to heart fail-
ure (2). Retention of functional cardiomyocytes is critical
in limiting subsequent adverse ventricular remodeling. In
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experimental models cardiomyocyte loss can be reduced
by intervention at the time of reperfusion, but successful
translation of these interventions to the clinic has been
limited (3, 4). Cardiomyocyte death also occurs in the
peri-infarct area during infarct healing and scar forma-
tion, leading to infarct expansion. Promotion of angio-
genesis during this phase can limit infarct expansion and
subsequent adverse remodeling (5–9).
Glucocorticoids (physiological cortisol and corticoste-
rone, as well as synthetic forms) are known to suppress
angiogenesis (10). Plasma levels of cortisol increase in the
hours after MI following activation of the hypothalamic-
pituitary-adrenal axis and may protect cardiomyocytes
from acute ischemic injury (11–13), but as circulating lev-
els are reduced within days of MI, they are unlikely to
impact on the later angiogenesis that is associated with
infarct healing. However, active glucocorticoids can also
be regenerated locally from circulating inert 11-keto me-
tabolites by the enzyme, 11-hydroxysteroid dehydroge-
nase type 1 (11-HSD1), that is expressed in many cells,
including in cardiomyocytes, fibroblasts, and smooth
muscle cells in the heart (14). Genetic disruption of
Hsd11b1, the gene encoding 11-HSD1 does not change
initial ischemic injury in the murine heart following ex-
perimental MI, but leads to enhancement of peri-infarct
vessel density (8, 10). Importantly, vessels formed during
infarct healing mature to maintain blood flow to the peri-
infarct area in 11-HSD1 deficient mice and increased
vessel density is associated with shorter and thicker in-
farcts and with retention of cardiac function (8). Pharma-
cological inhibitors of 11-HSD1 have reached phase 2
clinical development for use in diabetes and cognitive dys-
functionandhavepotential as anew therapeutic approach
for promotion of angiogenesis, including post-MI (15,
16). However, whether 11-HSD1 deficiency can prevent
maladaptive ventricular remodeling and progression to
heart failure following MI has not been examined.
11-HSD1activity is not detectable in endothelial cells,
but the enzyme is present in the vessel wall where expres-
sion and activity is associated with smooth muscle cells
(17, 18). Whether glucocorticoids regenerated by 11-
HSD1 in vascular smooth muscle cells act as an endoge-
nous brake upon angiogenesis in the healing infarct, or
indeed upon any aspect of ventricular remodeling after
MI, is unknown. A recent study has shown that myocar-
dial expression of 11-HSD1 is increased in an MI-inde-
pendent model of pathological hypertrophy and that ven-
tricular remodeling can be reversed by pharmacological
inhibition of 11-HSD1without any change in vessel den-
sity (19). This suggests that 11-HSD1 has effects in the
heart over and above those involving angiogenesis, poten-
tially via 11-HSD1 expressed in cardiomyocytes.
The present study tested the hypothesis that long term
maladaptive structural and functional myocardial remod-
elling and the development of heart failure following MI
are attenuated by 11-HSD1 deficiency. To establish the
contribution of 11-HSD1 specifically in vascular smooth
muscle cells and cardiomyocytes to the beneficial outcome
following MI seen in mice lacking the enzyme globally,
targeted deletion of 11-HSD1 in these cell types was
investigated.
Materials and Methods
Experimental Animals. All experiments involving animals
were approved by the University of Edinburgh Animal Welfare
and Ethical Review Body and by the UK Home Office. Experi-
ments used adult male (10–14 weeks of age) mice with global
deficiency on a C57Bl/6 genetic background (Hsd11b1-/-) (8,
20), with C57Bl/6 controls, or mice in which deletion was tar-
geted to vascular smooth muscle and cardiomyocytes (21, 22).
These Hsd11b1fl/flSm22-Cre (Hsd11b1CVCre) were gener-
ated by crossing Sm22-Cre mice with Hsd11b1fl/fl mice, ho-
mozygous for a “floxed” allele ofHsd11b1 (generated by Arte-
mis Pharmaceuticals, Cologne, Germany, directly onto a
C57BL/6J background). LoxP sites were placed flanking exon 3
of the mouseHsd11b1 gene, excision of which results in a “null
allele” by “out of frame splicing” from exon 2 to exon. Controls
wereHsd11b1fl/fl (Cre-) littermates (Hsd11b1CVCre-). Following
Cre genotyping, appropriate targeting was confirmed by deter-
mination of Hsd11b1 RNA and 11-HSD1 protein content in
myocardium, aorta, liver and skeletal muscle.
Induction of MI.Myocardial infarction (MI) was induced by
coronary artery ligation (CAL, as previously described (8, 23)) in
Hsd11b1-/- mice, in age matched C57Bl/6 mice (WT), in
Hsd11b1CVCre and inHsd11b1CVCre- mice. Briefly, following
injection of analgesic (buprenorphine, 0.05 mg/kg, s.c.) and in-
tubation for mechanical ventilation (120 strokes/min, 200l
stroke volume, HSE-Harvard MiniVent), the chest was opened
at the fourth intercostal space and the pericardiumwas removed
to allow ligation of the left anterior descending coronary artery
(LAD) (6–0Prolene suture,Ethicon). Succesful ligationwas con-
firmed by blanching of the left ventricle (LV), and the chest was
closed using a 5–0Mersilk suture (Ethicon), ensuring that no air
remained in the chest cavity. The skin was closed using 9 mm
stainless steel autoclips (HarvardApparatus). Following surgery
1.5ml sterile saline (0.9%, s.c.)was administered to aid recovery.
24h after induction of MI, a blood sample (45l) was collected
from the tail vein into a tube containing sodium citrate buffer for
assay of troponin I by ELISA (Life Diagnostics High Sensitivity
Mouse Cardiac Troponin-I ELISA Kit) to assess the extent of
injury (24).
Structural & Functional Characterization. 8 weeks after
coronary artery ligation surgery, cardiac structure, function and
infarct size was measured using magnetic resonance imaging
(MRI), as previously described (25). Temperature was main-
tained at 37°C, respiration rate at 50–60 breaths perminute and
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heart rate at 500–550 bpm during imaging in isoflurane (1.3–
1.8%) anesthetized mice. Animals were placed in a supine po-
sition inside a 7TMRI scanner (Agilent Technologies) with a 39
mm quadrature radiofrequency coil. Short axis cardiac images
were acquiredusing anECG-triggered and respiratory gated gra-
dient echo ‘cine’ sequence (TR/TE 7.3/2.7ms with a flip angle
of 15o) with gradient and RF spoiling. Nine consecutive 1 mm
thick slices from 12–13 time frames were acquired, which en-
compassed the entire heart from base to apex. The field of view
was 30 mmwith a 192 192 matrix and 4 averages were used.
ImageJ software (National Institutes of Health) was used to as-
sess left ventricular (LV) end diastolic volume, LV end systolic
volume, and ejection fraction. Infarct size was measured by seg-
menting each short axis image into 20 sections. Any section
which was thinned and akinetic or dyskinetic over the cardiac
cycle was designated as infarcted tissue. Gray scale contrast also
allowed visual confirmation of infarcted tissue. Infarct length
was quantified by adding together the endo and epicardial cir-
cumference of infarcted tissue and dividing this by the sumof the
total endo and epicardial circumferences.
After MRI mice were killed by cervical dislocation and the
lungs collected and weighed to assess pulmonary edema. Hearts
were weighed and either frozen at –80°C for subsequent RNA
extraction and analysis; or processed and embedded in paraffin
wax for histological and immunohistochemical analysis.
In a separate study, Hsd11b1CVCre and Hsd11b1CVCre-
mice underwent CAL for induction of MI as above, or sham
operation. Structure and function was investigated by high-res-
olutionultrasound (Vevo770HighResolutionUltrasoundScan-
ner (Visualsonics) 7 days after surgery. Briefly, long axis views of
theheart inECG-GatedKilohertzVisualization (EKV)modeand
M-mode were acquired in isoflurane (2%) anesthetized mice
placed on a heated table to maintain body temperature at 37°C,
heart rate was maintained in the range of 500–550 bpm. Ven-
tricular area at end systole (LV end systolic area, LVESA) and at
enddiastole (LV enddiastolic area, LVEDA)were collected from
EKV traces using Vevo Image Analysis Software (Visualsonics)
and this permitted calculation of EF (EF). Fractional shortening
(FS) was calculated from M-mode. In this study hearts were
perfusion fixed in situ and prepared for histological assessment
of infarct area, vessel density and macrophage content.
Molecular Analysis. RNA was extracted from homogenized
tissue using a Trizol Plus RNA Purification Kit (Invitrogen) ac-
cording to themanufacturers instructions. After confirmation of
RNA concentration and the A260/A280 ratio (Nanodrop 1000
Version 3.3, Thermo Scientific), each sample was DNase I
treated to remove genomic DNA. RNA was reverse transcribed
(High Capacity cDNA Reverse Transcription Kit, Applied Bio-
systems) and cDNA synthesis was performed in a thermal cycler
using the following conditions; 25°C for 10minutes, 48°C for 40
minutes, 95°C for 5 minutes, then cooled to 4°C. Hsd11b1 ex-
pression was assessed for each sample in triplicate using a Taq-
man Gene Expression Assay (Mm00476182_m1). For cardiac
genes qRT-PCR was performed to assess mRNA levels of atrial
natriuretic peptide (ANP, Nppa), Collagen12 (Col1a2), Col-
lagen 31 (Col3a1), transforming growth factor  (TGF,
Tgfb1), -myosin heavy chain ( –MHC,Myh6), and - myosin
heavy chain (-MHC, Myh7) using a Lightcycler 480 (Roche)
and the Taqman Fast Advanced template or the Roche FamHy-
drolysis (Roche) template as appropriate. The internal control
for all qRT-PCR experiments was -actin (Actb), which was
similar in all groups. Primers (Table S1) were designed in house
and prepared by Invitrogen. A standard curve was prepared by
pooling 2 l from each cDNA sample. and making serial dilu-
tions in RNase-free water.
Western Blotting. 11-HSD1 protein content was assessed by
Western blot as previously described (26), in the heart, liver,
aorta and skeletal muscle to confirm appropriate deletion in
Hsd11b1CVCremice. Briefly 50 mg of tissue was homogenized
in 300l lysis buffer (RIPA buffer (Sigma), protease& phospha-
tase inhibitor cocktails (Sigma) then centrifuged at 12 000 G for
15 minutes at 4°C. Proteins were separated by SDS-PAGE then
transferred (Trans-Blot Semi Dry Transfer Cell, Bio-Rad) to a
nitrocellulose membrane. After blocking (milk powder in TBS
bufferwithTween20) themembranewas incubatedovernight at
4°C with primary 11-HSD1 antibody (1/10000 in 5% BSA,
generated in house in sheep (26)). The membrane was washed
before application of horse radish peroxidase (HRP) conjugated
donkey-antisheep secondary antibody (1/5000, Abcam,
ab97125) then washed again and exposed to antimouse -actin
(1/10000, Cell Signaling Technologies) as a loading control, to
HRP conjugated rabbit antimouse secondary antibody (Abcam,
ab6728) then developed (ECL PrimeWestern BlottingDetection
Reagent (GE Healthcare) and exposed to X-ray film for detec-
tion. 11-HSD1protein levelswas calculated by normalizing the
density of this band to that of -actin protein.
Histological and Immunohistochemical Analysis. Infarct
area and thickness were assessed inMasson’s Trichrome stained
paraffin sections. The infarcted area was selected manually and
expressed as a percentage of the total area of the LV (Image Pro
6.2 and a Stereologer Analyzer 6 (MediaCybernetics)). Infarct
thickness was determined by averaging scar thickness from five
equally-spaced points along the length of the infarct. For mac-
rophages, slides were incubated overnight with biotinylated rat
antimouse Mac 2 (1/6000, Cedarlane), or for alternatively acti-
vated macrophages with rabbit antimouse Ym1 (1/500, Stem
Cell Technologies) followed by a biotinylated goat antirabbit
(Vector). Color was developed with a few drops of diaminoben-
zidine (DAB, Vector) according to the manufacturers instruc-
tions. A color threshold was set manually so as to only select
positive brown staining for Mac2 and the area of this positive
staining within the infarct was calculated automatically. Total
macrophage infiltration was then expressed as the percentage
area of positive brown DAB staining within the infarct. Peri-
infarct angiogenesis was assessed in tissue sections by detection
of immunoreactive CD31 (rabbit antimouse CD31 (1/50, Ab-
cam,) in PBS) with a biotinylated goat antirabbit (Vector) sec-
ondary antibody. DAB solution was added to each section for
visualization. Angiogenesis was assessed in 20 randomly as-
signed fields of view around the infarct border. The number of
CD31 vesselsweremeasured and categorised according to size;
capillaries (4 m diameter), small arterioles (4 – 200 m di-
ameter) and large arterioles (200 m diameter).
Cardiomyocyte cross-sectional area was assessed in isolectin
B4 (Alexa Fluor conjugated isolectin B4 (1/100, Thermo Fisher)
and wheat germ agglutinin (wheat germ agglutinin-rhodamine
(1/75, Vector) stained paraffin sections as previously described
(27). Five randomly selected regions of interestwere visualized in
the LV free wall. Adobe Photoshop CS5 Extended (Adobe) was
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used to calculate cross-sectional area in cardiomyocytes which
appeared to be cut in the short axis as judged by (a) a nucleus in
the middle of the cell and, (b) surrounded by capillaries which
were also cut in the short axis.
Statistical analysis. Prism 6f for Mac OS X (GraphPad Soft-
ware Inc) was used for 2 way ANOVA (7 day Hsd11b1CVCre
and Hsd11b1CVCre-, sham and MI) or two-tailed unpaired Stu-
dent’s t tests (comparisons of Hsd11b1-/- and WT, or
Hsd11b1CVCre andHsd11b1CVCre-) All values are expressed as
mean  SEM, statistical significance was accepted at P  .05.
Results
Global but not cardiomyocyte and vascular
smooth muscle cell disruption of Hsd11b1
prevents infarct thinning and expansion during
the development of heart failure
Hsd11b1 mRNA and 11-HSD1 protein levels were
both significantly reduced in the myocardium and aorta,
but not in liver or skeletalmuscle, ofHsd11b1CVCremice
relative to their littermate controls (Hsd11b1CVCre-), con-
sistent with selective disruption of gene expression in car-
diomyocytes and vascular smooth muscle directed by
SM22--Cre (Figure 1) (21). Blood pressure, contractile
function and heart weight:body weight ratio were not sig-
nificantly different towild typemice (Supplemental Figure
1). Troponin I in plasma collected from the tail vein 24h
after coronary artery ligation, a measure of ischemic in-
jury, increased to over 40 ng/ml in all groups (Supplemen-
tal Figure 2), confirming that the extent of the initiating
myocardial injury is not influenced by 11-HSD1 defi-
ciency (8). In contrast,when injurywasassessedat8weeks
afterMI (Figure 2), either in vivo byMRI or in histological
sections, infarct area was significantly less (P  .05) and
average thickness was significantly greater (P  .005) in
mice with global 11-HSD1 deficiency compared to their
WT controls. This attenuation of infarct expansion was
not seen in Hsd11b1CVCre relative to their
Hsd11b1CVCre- littermate controls (Figure 2c).
Ventricular dilation is reduced and function
improved in mice with global, but not
cardiomyocyte and vascular smooth muscle cell,
depletion of Hsd11b1
Analysis of structural and functional remodeling by
MRI 8 weeks after induction of MI revealed a significant
reduction in LV end-diastolic and end-systolic volumes in
micewith global, but not tissue-specific, depletion of 11-
HSD1 (Figure 3a, P  .05). Ejection fraction was in-
creased by 41  9% in Hsd11b1-/- mice (Figure 3b, P 
.05), consistent with greater retention of contractile func-
tion in this group only. Lungs collected from Hsd11b1-/-
mice 8 weeks after induction ofMI were also significantly
lighter (Figure 3c, P  .05) than WT mice or mice with
tissue-specific deletion, suggesting that Hsd11b1-/- mice
have reduced tendency to develop pulmonary edema.
Global but not cardiomyocyte and vascular
smooth muscle cell depletion of Hsd11b1-/- reduces
cardiac hypertrophy and expression of fetal genes
MRI analysis conducted at 8 weeks after induction of
MI revealed a reduction inmyocardial mass inHsd11b1-/-
(120 7.3mg) compared toWTmice (160 5.7mg,P
.01) and this was confirmed by postmortem gravimetric
analysis (Figure 4a, P  .001). Reduced hypertrophic re-
modeling in hearts from Hsd11b1-/- mice was evidenced
by a significant decrease in cardiomyocyte cross sectional
area (Figure 4b, P .05) and in the expression of the fetal
cardiomyocyte markers -MHC (relative to -MHC, P
.05) and ANP (P .01, Figure 4c), compared to theirWT
controls. Expression of the profibrotic genes TGFB1, and
the Col1a2 and Col3a1 genes encoding the major colla-
gens, was unaffected by global or cardiovascular specific
deficiency of 11-HSD1 (Figure 5).
Peri-infarct angiogenesis and infarct expansion at
7 days after induction of MI are not influenced by
cardiomyocyte and vascular smooth muscle
selective depletion of Hsd11b1
As long term outcomes following MI were not im-
proved when Hsd11b1 disruption was restricted to car-
diomyocytes and vascular smooth muscle, a further study
was conducted to investigate early wound healing and
infarct expansion in these mice. By 7 days after induction
of MI, during infarct repair, high resolution ultrasound
showed that the extent of LV dilation and loss of function
was similarly impaired in all mice relative to sham-oper-
ated mice (Figure 6a). Cardiomyocyte and vascular
smooth muscle restricted deletion ofHsd11b1 also failed
to influence infarct size (Figure 6b) or the extent of peri-
infarct angiogenesis during infarct healing (Figure 6c).
Macrophage recruitment was increased post-MI relative
to shamoperation (Figure 6d), but neither recruitment nor
polarization of macrophages towards a YM-1 positive
‘M2’ macrophage phenotype was influenced in hearts
from Hsd11b1CVCre compared to Hsd11b1CVCre- mice
(Figure 6d).
Discussion
In this study we present three important findings: (1) that
11HSD1 amplifies infarct expansion and progression to
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heart failure after MI, supporting the use of pharmaco-
logical inhibitors of 11HSD1 toprevent the development
of heart failure in this setting; (2) that disruption of the
Hsd11b1 gene in cardiac muscle does not prevent the ex-
pression of fetal genes or hypertrophic remodeling after
MI suggesting that 11HSD1 in cardiomyocytes does not
play a direct role in regulating this process; (3) that the
promotion of peri-infarct angiogenesis associated with
prevention of early infarct expansion in mice with global
11HSD1 deficiency (8) does not involve 11HSD1 in
smooth muscle cells of the vessel wall.
FollowingMI, ventricular remodeling and heart failure
develop in response to loss of contractilemyocardial tissue
that is not replaced after injury. The extent of this early
injury is a key determinant of long-term outcome (28). In
the present study, initial myocardial ischemic injury, as
assessed by plasma levels of cardiac troponin I, was not
influenced by 11-HSD1 deficiency, confirming our pre-
vious observations where infarct injury was assessed di-
rectly early after MI (8). Glucocorticoids can protect the
heart from ischemic injury, and systemic glucocorticoid,
increased as a result of HPA activation in response toMI,
Figure 1. Confirmation of cardiovascular specific 11-HSD1 deletion. Hsd11b1 mRNA and 11-HSD1 protein were assessed by rt-PCR
(normalized to -actin housekeeping gene) and Western blotting (normalized to -actin loading control) respectively in heart, aorta, liver and
skeletal muscle from Hsd11b1fl/flSm22-Cre (Hsd11b1CVCre) and control Hsd11b1fl/flSm22-Cre- (Hsd11b1CVCre-) mice. Expression in
hsd11b1CVCre is expressed relative to maximum achieved in tissue from Hsd11b1CVCre- *** P  .001, **  P  .01 vs parallel control; n  4/
group.
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is dominant in the first 24h after MI. We have already
shown that this early peak in plasma glucocorticoid con-
centration after MI is not altered in 11-HSD1 deficient
mice, therefore it is not surprising that early injury is also
unaffected in these mice (8). However by 8 weeks after
induction of injury the infarct had expanded and thinned
to a lesser degree in mice with global deficiency of 11-
HSD1, and this was associated with less ventricular dila-
tion, a key prognostic indicator of outcome in human
heart failure (2, 29). Decreased dilation in the present
studywasaccompaniedbydiminished expressionofANP,
consistent with lowered wall stress (30), as well as reduc-
tion of ventricular dysfunction and pulmonary edema, to-
gether indicating prevention of progression to heart fail-
ure. This outcome is consistent with a detrimental
influence of 11-HSD1onwoundhealing and remodeling
that occur in response to injury.
Replacement of damaged myocardium by noncontrac-
tile scar tissue induces cardiomyocytes in the noninfarcted
ventricle to undergo hypertrophic remodelling to main-
tain cardiac output, resulting in an increase in myocardial
mass. Here, heart mass, assessed either in vivo byMRI, or
ex vivo gravimetrically, was reduced in mice with global
deficiency in 11-HSD1. As well as increased cross-sec-
tional area, cardiomyocytes undergoing pathological hy-
pertrophy show re-expression of fetal genes, including
those encoding ANP and  myosin
heavy chain (MHC). Increased ex-
pression of MHC relative to the
adult MHC isoform is associated
with loss of cardiomyocyte contrac-
tility in murine models (31). In the
present study it is clear that global
deficiency in 11-HSD1 suppresses
hypertrophic remodeling and re-
duces re-expression of fetal genes
consistent with retention of function
and reduction of wall stress. Recent
data have linked a common varia-
tion in theHsd11b1 gene to LVmass
inman (32).Reversal of pathological
hypertrophy by pharmacological in-
hibition of 11-HSD1 in an MI-in-
dependent murine model also sup-
ports a specific role for 11-HSD1 in
the regulation of cardiomyocyte hy-
pertrophy (19). However, neither
modification of fetal genes, nor
changes in myocyte cross sectional
area were observed when Hsd11b1
deletion was limited to cardiomyo-
cytes and vascular smooth muscle.
This is consistent with a mechanism
that is dependent on prohypertro-
phic signaling from other cells in the
heart that express 11-HSD1. In-
deed, residual expression of
Hsd11b1, evident in RNA and pro-
tein analysis of hearts from
Hsd11b1Creve mice, supports sites
of expression in the heart over and
above cardiomyocytes and vascular
smooth muscle. Transcriptomic
analysis has revealed that Hsdl11b1
is enriched 6-fold in cardiac fibro-
Figure 2. Global, but not cardiovascular specific, 11-HSD1 deficiency reduces infarct expansion
post-MI. Infarct injury was compared in wild type (WT) and global 11-HSD1 deficient mice
(Hsd11b1-/-), and in mice with cardiomyocyte and vascular smooth muscle specific deletion
(Hsd11b1CVCre) and respective control (Hsd11b1CVCre-) at 8 weeks after induction of MI by (top
panel) MRI and by (lower panels) histology (Masson’s trichrome, MT) to determine infarct area
and infarct thickness. Paired groups were compared by Student’s t test * P  .05, ** P  .01,
*** P  .005; n  6–8/group.
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blasts relative to fibroblasts from other sources (33). Fi-
broblasts release a number of immunomodulatory and
hypertrophy regulating factors and could be a key site for
local regulation of cardiomyocyte growth during remod-
eling (34, 35). 11-HSD1 has previously been shown to
regulate the release of inflammatorymediators in synovial
fibroblasts (36, 37), and this mechanism merits further
investigation in the heart. Resident or recruited myeloid
cells also express Hsd11b1 and can regulate cardiomyo-
cyte hypertrophy (38, 39). Alternatively, if infarct size is
the primary driver for adaptive hypertrophy followingMI
(28), then reduction of infarct expansion in mice with
global 11-HSD1 deficiencymay be sufficient to diminish
changes in cardiomyocyte gene expression and size. It is
feasible that loss of 11-HSD1 in other organs eg, the
kidneyhave indirect effects onhemodynamic stress during
the development of heart failure.
We have previously demonstrated that peri-infarct an-
giogenesis during infarct healing is enhanced in globally
11-HSD1deficientmice (8, 10) and that this is associated
with development of shorter and thicker infarcts (8).
Hsd11b1 is expressed in the smooth muscle, but not the
Figure 3. Global, but not cardiovascular, 11-HSD1 deficiency reduces LV dilatation, loss of contractile function and pulmonary edema after MI.
Structural (a) and functional (b) remodelling was compared by MRI in wild type (WT) and global 11-HSD1 deficient mice (hsd11b1-/-), and in mice
with cardiomyocyte and vascular smooth muscle specific deletion (hsd11b1CVCre) and respective floxed control (hsd11b1CVCre-) at 8 weeks after
induction of MI by coronary artery ligation. The middle panels show 4 chamber views collected by cine-MRI at end-systole (top) and end-diastole
(bottom). Lungs were collected from mice after imaging and weighed to detect pulmonary edema (c). Paired groups were compared by Student’s t
test * P  .05, ** P  .01, *** P  .005; n  6–8/group.
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Figure 4. Hypertrophic remodeling and expression of fetal genes are inhibited in mice with global, but not cardiovascular, 11HSD1 deficiency.
Heart:body weight ratio (a) and cardiomyocyte cross-sectional area (b) were compared in mice global 11-HSD1 deficient mice (Hsd11b1-/-) and
wild-type (WT) controls, and in mice with cardiomyocyte and vascular smooth muscle specific deletion (Hsd11b1CVCre) compared to respective
floxed control (Hsd11b1CVCre-) at 8 weeks after induction of MI by coronary artery ligation. (c) Expression of fetal genes atrial natriuretic peptide
(ANP (Nppa)), upper panel) and  myosin heavy chain (MHC (Myh6), expressed relative to MHC (Myh7), lower panel) was determined by real-
time PCR. * P  .05, ** P  .01, *** P  .005 vs matched control; n  6–8/group.
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endothelium, of murine vasculature (17), where it regu-
lates inflammation and neointimal proliferation (40, 41).
It has been suggested that 11-HSD1 in the vessel wall
may contribute to regulation of angiogenesis (10). How-
ever, in the present study targeted deletion of 11-HSD1
in vascular smooth muscle failed to recapitulate enhance-
ment of peri-infarct angiogenesis followingMI. Enhance-
ment of angiogenesis was previously linked to promotion
of alternative macrophage activation during early infarct
healing in globally Hsd11b1 deficient mice (8), this was
also absent in mice with targeted deletion of Hsd11b1 in
cardiomyocytes andvascular smoothmuscle.Again, other
cells present in the heart, including fibroblasts and my-
eloid cells, express 11-HSD1 and can release molecules
that regulate inflammationandangiogenesis (36–38), and
these sites may be important for the effects of global 11-
HSD1 deficiency on infarct healing post-MI. Alternative
macrophage activation can also promote fibrosis (42), po-
tentially having a detrimental influence on cardiac func-
tion in the longer term.However, therewas no evidence in
the present study for an influence of 11-HSD1 deficiency
on the expression of a range of fibrosis associated genes in
the failing LV.
The discussions above are focused around the principal
that the primary function of 11-HSD1 is to modulate
intracellular availability of active glucocorticoid metabo-
lites. Evidence is provided for appropriate reduction of
gene expression and protein content in mice with targeted
deletion of Hsdl11b1, but a limitation of the study is the
lack of direct evidence for reduction of active glucocorti-
coid regeneration through 11-HSD1 activity in the tar-
geted cells. While it is not therefore possible to state con-
clusively that reduced availability of locally generated
glucocorticoids is key for the study outcomes, this limita-
tion does not detract from the conclusion that 11-HSD1
is a valid therapeutic target in the heart following MI.
A number of pharmacological inhibitors of 11-HSD1
have been developed for the treatment of atherosclerotic
Figure 5. Fibrotic gene expression post-MI is not influenced by 11-HSD1 Myocardial Col1a2 (upper panel), Col3a1 (middle panel) and Tgfb1
(lower panel) expression determined by qRT-PCR in hearts from wild type mice (WT), mice with global depletion of 11-HSD1 (Hsd11b1-/-), mice
with deletion in cardiac and vascular smooth muscle cells (Hsd11b1CVCre) and floxed Cre –ve controls (Hsd11b1CVCre-); n  6–8/group).
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and metabolic disease (15). We have found that 11-
HSD1 inhibitor can promote early angiogenesis and pre-
vent infarct expansion when given immediately after MI
(16), the present data suggests that pharmacological 11-
HSD1 inhibition also has the potential to reduce progres-
sion toheart failure.Theuseofmineralocorticoid receptor
Figure 6. Cardiovascular selective deletion of 11HSD1 does not modify early infarct healing Structural and functional remodelling (a), infarct size
(b), peri-infarct angiogenesis (c), macrophage density and polarization (e), were all comparable in Hsd11b1CVCreve and control floxed mice
(Hsd11b1CVCreve) mice during infarct healing 7 days after induction of MI. Left ventricular end diastolic area (LVEDA), LV end systolic area (LVESA),
fractional shortening (FS) and EF (EF) were assessed by high resolution ultrasound in mice 7 days after induction of MI by coronary artery ligation,
or sham operation (sham). Macrophages were identified by immunoreactivity for the secreted protein Mac-2 (d, upper panel) and alternatively
activated macrophages by expression of immunoreactive Ym-1 (d, lower panel). ** P  .01, *** P  .005. vs sham of same genotype, n 
8/group.
Table 1.
Peptide/protein
target
Antigen sequence
(if known) Name of Antibody
Manufacturer, catalog #, and/or name
of individual providing the antibody Species raised in; monoclonal or polyclonal
Dilution
used
Mac-2 (Galectin-3) Anti-mouse/human Mac-2 Cedarlane, CL8942AP Rat, monoclonal 1 in 6000
Ym-1 (ECF-L) Ym1 antibody Stem Cell Technologies, 01 404 Rabbit, polyclonal 1 in 500
CD 31 (Pecam) Anti-CD-31 antibody Abcam, ab28364 Rabbit, polyclonal 1 in 50
Isolectin B4 Isolectin GS-IB4 from griffonia simplifolica Thermo Fisher, I21413 rabbit 1 in 100
wheat germ agglutinin Rhodamine labelled wheat germ agglutinin Vector Laboratoroes RL-1022 goat 1 in 75
-actin -actin antibody Cell Signalling Technology, 4967S Rabbit, polyclonal 1 in 1000
11-HSD1 11-HSD1 Prof Karen Chapman sheep 1 in 1000
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(MR) antagonists in patientswith heart failure is nowwell
established (43). Recent clinical and experimental studies
have highlighted additional benefits of MR antagonists
when given early after MI, that include promotion of an-
giogenesis and prevention of infarct expansion (44, 45).
Studies inmicewith cardiomyocyte-restricted inactivation
of the MR gene suggest that the clinical benefits of MR
blocking therapy in MI and heart failure are mediated
largely via cardiomyocyte-dependent mechanisms (46).
As the present data show that the effects ofHsd11b1 gene
targeting are cardiomyocyte independent, 11-HSD1 in-
hibitors may offer additional benefits in patients already
receiving MR antagonist therapy or an alternative in pa-
tients for whom hyperkalemia precludes the use of MR
antagonists (47).
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